These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 15987071)

  • 21. Translating pharmacogenomics: challenges on the road to the clinic.
    Swen JJ; Huizinga TW; Gelderblom H; de Vries EG; Assendelft WJ; Kirchheiner J; Guchelaar HJ
    PLoS Med; 2007 Aug; 4(8):e209. PubMed ID: 17696640
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of genomics in drug discovery.
    Ward SJ
    Biotechniques; 2001 Sep; 31(3):626, 628, 630, passim. PubMed ID: 11570506
    [No Abstract]   [Full Text] [Related]  

  • 23. Scanning the human genome and the horizon: the potential and pitfalls of pharmacogenetics and stratified medicine.
    Jennings BA; Shakespeare T; Loke YK
    Br J Gen Pract; 2015 Jun; 65(635):284-5. PubMed ID: 26009508
    [No Abstract]   [Full Text] [Related]  

  • 24. Pharmacogenetic testing in psychiatry: a review of features and clinical realities.
    de Leon J; Arranz MJ; Ruaño G
    Clin Lab Med; 2008 Dec; 28(4):599-617. PubMed ID: 19059065
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The information revolution reaches pharmaceuticals: balancing innovation incentives, cost, and access in the post-genomics era.
    Rai AK
    Univ Ill Law Rev; 2001; 2001(1):173-210. PubMed ID: 16493845
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 'The future of cancer treatment'.
    O'Keefe B
    Fortune; 2001 Jul; 144(2):80. PubMed ID: 11471358
    [No Abstract]   [Full Text] [Related]  

  • 27. Implications of pharmacogenomics for drug development.
    Kirk RJ; Hung JL; Horner SR; Perez JT
    Exp Biol Med (Maywood); 2008 Dec; 233(12):1484-97. PubMed ID: 18849536
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacogenetics--pivotal to the future of the biopharmaceutical industry.
    Foot E; Kleyn D; Palmer Foster E
    Drug Discov Today; 2010 May; 15(9-10):325-7. PubMed ID: 20298799
    [No Abstract]   [Full Text] [Related]  

  • 29. Novel technology and the development of pharmacogenetics within the pharmaceutical industry.
    Gibson N; Jawaid A; March R
    Pharmacogenomics; 2005 Jun; 6(4):339-56. PubMed ID: 16004553
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Progress in pharmacogenomics and its promise for medicine.
    Blake CA; Sobel BE
    Exp Biol Med (Maywood); 2008 Dec; 233(12):1482-3. PubMed ID: 18849537
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drug evaluation, drug development and pharmacogenetics: celebrating 30 years of progress.
    Li Wan Po A
    J Clin Pharm Ther; 2005 Feb; 30(1):1-4. PubMed ID: 15658998
    [No Abstract]   [Full Text] [Related]  

  • 32. Personalized medicine: boon or budget-buster?
    Dean CE
    Ann Pharmacother; 2009 May; 43(5):958-62. PubMed ID: 19417115
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drug companies accused of stalling tailored therapies.
    Sinha G
    Nat Med; 2006 Sep; 12(9):983. PubMed ID: 16960561
    [No Abstract]   [Full Text] [Related]  

  • 34. Developmental biology's impact on drug development.
    Cohen CM; Platika D; Scangos G; Kilian P
    Nat Biotechnol; 1998 Jul; 16(7):628-31. PubMed ID: 9661194
    [No Abstract]   [Full Text] [Related]  

  • 35. The value of routine pharmacogenomic screening-Are we there yet? A perspective on the costs and benefits of routine screening-shouldn't everyone have this done?
    Veenstra DL
    Clin Pharmacol Ther; 2016 Feb; 99(2):164-6. PubMed ID: 26565561
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Pharmacogenetics--new therapeutic possibilities].
    Ainsworth MA; Nielsen OH
    Ugeskr Laeger; 2005 May; 167(20):2141. PubMed ID: 15987067
    [No Abstract]   [Full Text] [Related]  

  • 37. [Drug development costs are overstated by the industry].
    Jeppsson A
    Lakartidningen; 2006 Mar 1-7; 103(9):663-4; discussion 664. PubMed ID: 16583545
    [No Abstract]   [Full Text] [Related]  

  • 38. The critical path of warfarin dosing: finding an optimal dosing strategy using pharmacogenetics.
    Lesko LJ
    Clin Pharmacol Ther; 2008 Sep; 84(3):301-3. PubMed ID: 18714317
    [No Abstract]   [Full Text] [Related]  

  • 39. Pharmacogenomics: the promise of personalized medicine.
    Hood E
    Environ Health Perspect; 2003 Aug; 111(11):A581-9. PubMed ID: 12928155
    [No Abstract]   [Full Text] [Related]  

  • 40. [Drug targets: identification and evaluation].
    Mikkelsen JD
    Ugeskr Laeger; 2005 May; 167(20):2156-60. PubMed ID: 15987072
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.